[Stephen Kim, Edaily Reporter] Korean pharmaceutical and biotech stocks saw sharply divergent performance on November 16 as investors reacted to clinical news.
Corestem ChemOn hit the daily upper limit after clarifying its U.S. approval pathway, and AriBio Lab jumped more than 27% ahead of a key Alzheimer’s trial result from its affiliate. HLB Therapeutics fell by the daily limit following a failure in its U.S. Phase 3 trial.
AriBio Lab stock trend (From Naver Stock)
AriBio Lab surges 27% ahead of AR1001 Phase 3 results
According to KG Zeroin MP Doctor, AriBio Lab closed up 1,240 won (27.13%) at 5,810 won. That is more than triple its late-July low of 1,824 won.
The rally came ahead of results from affiliate AriBio’s global Phase 3 trial (POLARIS-AD) of AR1001 (mirodenafil), an oral Alzheimer’s drug candidate. The results will be presented during the opening oral session of CTAD 2026 in Boston, expected early on November 17, Korea time. The trial enrolled 1,535 patients across 13 countries, and 1,348 of them completed 52 weeks of treatment. The results will determine whether AriBio files a New Drug Application with the FDA.
“Today’s rise appears to reflect tomorrow morning’s topline announcement,” an AriBio official said. “Employees naturally have high expectations, but even at our level, the outcome is still unknown.”
AR1001 is a PDE5 inhibitor that works through several mechanisms, including improving cerebral blood flow and protecting neurons. Leqembi and Kisunla are antibodies administered intravenously every two to four weeks. AR1001 is a once-daily pill with a lower risk of ARIA. AriBio has signed an option and license agreement worth up to $4.7 billion with China’s Fosun Pharma.
Since AriBio is not publicly traded, investors are treating AriBio Lab, AriBio Holdings, and Samjin Pharmaceutical as the stocks most directly exposed to the results.
Corestem ChemOn
Corestem ChemOn Hits Upper Limit on FDA Pathway
Corestem ChemOn rose 417 won (30.00%) to close at the upper limit of 1,807 won. It had fallen to 1,300 won early in the session.
The company announced that it had received the official minutes of its Type C meeting with the FDA regarding Neuronata-R (lenzumestrocel), its stem cell therapy for ALS. The FDA agreed to a new randomized, double-blind, placebo-controlled Phase 3b confirmatory trial. The company would then file a Biologics License Application (BLA).
The FDA raised no major objections to the proposed primary endpoint—the change in the ALSFRS-R total score at week 24. It also indicated that it is open to accepting data from trials conducted in Korea that comply with ICH guidelines.
“The minutes have clarified our path to U.S. approval through a Phase 3b confirmatory trial,” said CEO Yang Gil-an.
HLB Therapeutics
HLB Therapeutics Hits Lower Limit
HLB Therapeutics fell 700 won (29.98%) and remained at the lower limit of 1,635 won for the entire trading session.
Its U.S. subsidiary, ReGenTree, announced that the U.S. Phase 3 trial (SEER-2) of RGN-259, an eye drop for neurotrophic keratitis, failed to achieve statistical significance for its primary endpoint—the complete healing rate at four weeks. This marks the drug candidate’s second Phase 3 failure, following the European SEER-3 trial.
“We will thoroughly analyze the full dataset and carefully review our future development plans,” said CEO Ahn Ki-hong.
Korea Ratings (KRI) took the top spot in the “Credit Rating Reliability” category of the 37th Edaily Survey of Credit Rating Experts (SRE), maintaining its number one position for the fifth consecutiv…
CJ CheilJedang Corp. is taking steps to create a sustainable and safe sports environment by utilizing the biodegradable biomaterial “PHA” (polyhydroxyalkanoates). The company plans to introduce PHA-ba…
Korean pharmaceutical and biotech stocks saw sharply divergent performance on November 16 as investors reacted to clinical news. Corestem ChemOn hit the daily upper limit after clarifying its U.S. app…